Version 1

Anacetrapib

Medicine

Extended indication Hypercholesterolemie, gemengde dyslipidemie, preventie van ernstige coronaire incidenten (Primary Hypercholesterolaemia or mixed dyslipidaemia, inclu
Therapeutic value No judgement
Registration phase Unknown

Product

Active substance Anacetrapib
Domain Cardiovascular diseases
Main indication Unknown
Extended indication Hypercholesterolemie, gemengde dyslipidemie, preventie van ernstige coronaire incidenten (Primary Hypercholesterolaemia or mixed dyslipidaemia, including reduction in cardiovascular mortality and morbidity in patients at high risk of CV events, in combination with a statin).
Manufacturer MSD
Mechanism of action Unknown
Route of administration Unknown
Therapeutical formulation Unknown
Budgetting framework Unknown
Additional remarks November 2017: Fabrikant geeft aan dat er geen aanvraag ingediend gaat worden.

Registration

Registration route Unknown
Type of trajectory Unknown
Particularity Unknown
ATMP Unknown
Orphan drug Unknown
Registration phase Unknown

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information